Elevai Labs INC DEF 14A proxy statements

PMGC Holdings Inc. announced its 2025 Annual Meeting agenda, revealing a combined 1:4,900 reverse stock split, a new $20 million dilutive equity line of credit, and ongoing related-party consulting agreements.

PMGC Holdings Inc. has secured an equity line of credit for up to $20 million, approved by majority shareholders, which will result in significant dilution for existing common stockholders.

PMGC Holdings Inc. adopted a new 2025 Equity Incentive Plan and significantly increased its authorized capital stock to 2.5 billion shares, approved by majority shareholders.

PMGC Holdings is holding a special meeting on March 26, 2025, to vote on proposals including increasing authorized common stock, implementing a staggered board, and approving bonus issuances of preferred stock to executives.

Elevai Labs Inc. is re-domesticating from Delaware to Nevada, becoming PMGC Holdings Inc., to eliminate Delaware franchise tax obligations.

Elevai Labs Inc. has increased its authorized shares to 2.5 billion through a written consent of majority shareholders, aiming for greater flexibility in future corporate actions.

Elevai Labs Inc. has approved an amendment to its Certificate of Incorporation to increase the total number of authorized shares to 2.5 billion, consisting of 2 billion common shares and 500 million preferred shares.

Elevai Labs Inc. will re-domesticate from Delaware to Nevada, becoming PMGC Holdings Inc., to eliminate Delaware franchise tax obligations.

Elevai Labs Inc. announces shareholder approval via written consent for the issuance of common stock and adjustments to warrants, as part of a securities purchase agreement with institutional investors.

Elevai Labs Inc. will implement a reverse stock split, ranging from 1:2 to 1:200, to boost its stock price and maintain its Nasdaq listing.

Elevai Labs Inc. will implement a reverse stock split, ranging from 1:2 to 1:200, to boost its stock price and maintain its Nasdaq listing.